NASDAQ$PROK
ProKidney Corp · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
ProKidney Corp reported a net loss of $42.6 million for Q1 2026 as it advanced its Phase 3 PROACT 1 trial for rilparencel.
ProKidney Corp, a late-clinical-stage biotech developing autologous cell therapies for chronic kidney disease, posted revenue of $226 thousand from facility leasing and a net loss of $42.6 million for the three months ended March 31, 2026. Operating expenses rose to $45.2 million, driven by increased clinical trial and manufacturing costs for the ongoing Phase 3 study, while cash and marketable securities totaled $225 million at quarter end. The company continues to focus on enrollment in PROACT 1 with topline surrogate endpoint data expected in Q2 2027.
- Revenue remained minimal at $226 thousand, consisting solely of lease income from Winston-Salem facilities.
- Net loss widened to $42.6 million from $38.0 million in Q1 2025, reflecting higher R&D spend of $33.8 million on the Phase 3 PROACT 1 trial.
- Cash, cash equivalents and marketable securities totaled $224.9 million, providing runway into mid-2027.
- Weighted average Class A shares outstanding were 141.9 million, resulting in basic and diluted EPS of $(0.14).
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$226K
Forward guidance
No quantitative financial guidance provided; company highlighted clinical timelines for PROACT 1.
Tailwinds
- RMAT designation maintained for rilparencel
- Phase 3 enrollment ongoing with amended protocol focusing on Stage 4 and late Stage 3b CKD patients
Headwinds
- Topline surrogate endpoint data not expected until Q2 2027
- Confirmatory endpoint data anticipated only in H2 2029
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2026
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro